Showing 1 to 10 of 10 results
Chinese Biotech Firm's Lung Cancer Breakthrough Shakes Up Global Pharma Industry
Akeso, a Chinese biotech firm, surprised the world by decisively beating Merck's leading lung cancer drug in clinical trials, marking a significant shift in global pharmaceutical innovation from the US to China, attracting major investments and raising concerns in the US.
Chinese Biotech Firm's Lung Cancer Breakthrough Shakes Up Global Pharma Industry
Akeso, a Chinese biotech firm, surprised the world by decisively beating Merck's leading lung cancer drug in clinical trials, marking a significant shift in global pharmaceutical innovation from the US to China, attracting major investments and raising concerns in the US.
Progress
44% Bias Score
Trump's MFN Drug Pricing Proposal: A Recipe for Reduced Access and Innovation
President Trump's proposed MFN policy for Medicaid drug pricing, mirroring the lowest prices in other developed nations, would severely reduce access to new medicines and hinder pharmaceutical innovation in the U.S., as those countries have price controls resulting in limited drug availability and s...
Trump's MFN Drug Pricing Proposal: A Recipe for Reduced Access and Innovation
President Trump's proposed MFN policy for Medicaid drug pricing, mirroring the lowest prices in other developed nations, would severely reduce access to new medicines and hinder pharmaceutical innovation in the U.S., as those countries have price controls resulting in limited drug availability and s...
Progress
52% Bias Score
Chinese Biotech Drug Outperforms Keytruda in Clinical Trials
Akeso's new lung cancer drug, Ivonescimab, outperformed Merck's Keytruda in Chinese clinical trials, extending progression-free survival; this success, coupled with increased licensing deals, highlights the rise of China's pharmaceutical innovation, though challenges in consumer trust and regulatory...
Chinese Biotech Drug Outperforms Keytruda in Clinical Trials
Akeso's new lung cancer drug, Ivonescimab, outperformed Merck's Keytruda in Chinese clinical trials, extending progression-free survival; this success, coupled with increased licensing deals, highlights the rise of China's pharmaceutical innovation, though challenges in consumer trust and regulatory...
Progress
48% Bias Score
IRA's Drug Price Controls Threaten Generic Drug Market
The Inflation Reduction Act's (IRA) price negotiation provision for prescription drugs, while intending to lower costs, risks undermining the generic drug market by reducing profit incentives for generic manufacturers, potentially limiting patient access to affordable medications and decreasing inno...
IRA's Drug Price Controls Threaten Generic Drug Market
The Inflation Reduction Act's (IRA) price negotiation provision for prescription drugs, while intending to lower costs, risks undermining the generic drug market by reducing profit incentives for generic manufacturers, potentially limiting patient access to affordable medications and decreasing inno...
Progress
60% Bias Score
Frequent 'Miracle Drug' Innovations Predicted Due to Technological Advancements
Former U.S. Treasury Secretary Larry Summers predicts a "miracle drug" innovation every couple of years due to technological advancements, particularly in life sciences, as exemplified by the success of semaglutides, while Novartis CEO Vas Narasimhan cautions that a comprehensive approach is needed ...
Frequent 'Miracle Drug' Innovations Predicted Due to Technological Advancements
Former U.S. Treasury Secretary Larry Summers predicts a "miracle drug" innovation every couple of years due to technological advancements, particularly in life sciences, as exemplified by the success of semaglutides, while Novartis CEO Vas Narasimhan cautions that a comprehensive approach is needed ...
Progress
44% Bias Score
Weight-Loss Injections Show Promise in Extending Lifespans, Preventing Diseases
New weight-loss injections, GLP-1 agonists like Mounjaro and Wegovy, show promise in delaying age-related illnesses and reducing heart attack risk by half, based on a 17,000-patient trial, leading experts to suggest expanded access for up to half of Britons to improve health and longevity.
Weight-Loss Injections Show Promise in Extending Lifespans, Preventing Diseases
New weight-loss injections, GLP-1 agonists like Mounjaro and Wegovy, show promise in delaying age-related illnesses and reducing heart attack risk by half, based on a 17,000-patient trial, leading experts to suggest expanded access for up to half of Britons to improve health and longevity.
Progress
52% Bias Score
AstraZeneca Invests $2.5 Billion in China R&D Center
AstraZeneca is investing $2.5 billion in a new research and development center in Beijing, its sixth globally, to leverage China's growing pharmaceutical innovation and establish a key hub for global drug development, reflecting China's rising role in the industry and resulting in collaborations wit...
AstraZeneca Invests $2.5 Billion in China R&D Center
AstraZeneca is investing $2.5 billion in a new research and development center in Beijing, its sixth globally, to leverage China's growing pharmaceutical innovation and establish a key hub for global drug development, reflecting China's rising role in the industry and resulting in collaborations wit...
Progress
48% Bias Score
Chinese Biotech Drug Outperforms Keytruda in Clinical Trials
Akeso, a Chinese biotech company, developed Ivonescimab, a lung cancer drug that outperformed Merck's Keytruda in clinical trials, resulting in a stock surge for its US partner and showcasing China's rising pharmaceutical innovation.
Chinese Biotech Drug Outperforms Keytruda in Clinical Trials
Akeso, a Chinese biotech company, developed Ivonescimab, a lung cancer drug that outperformed Merck's Keytruda in clinical trials, resulting in a stock surge for its US partner and showcasing China's rising pharmaceutical innovation.
Progress
40% Bias Score
CMS Drug Price Controls Under IRA Threaten Pharmaceutical Innovation
CMS announced price negotiations for 15 drugs under the IRA, imposing penalties up to 95% of U.S. sales for non-compliance; this discourages R&D, potentially resulting in fewer new drugs and harming patients, with studies projecting a loss of 135 new drugs and $663 billion in R&D spending by 2039.
CMS Drug Price Controls Under IRA Threaten Pharmaceutical Innovation
CMS announced price negotiations for 15 drugs under the IRA, imposing penalties up to 95% of U.S. sales for non-compliance; this discourages R&D, potentially resulting in fewer new drugs and harming patients, with studies projecting a loss of 135 new drugs and $663 billion in R&D spending by 2039.
Progress
60% Bias Score
Viagra ODF: New Orally Dissolving Film Version Developed
Viatris developed Viagra ODF, an orally dissolving film version of Viagra, launched in Canada in September 2023 and with a UK trademark application filed, offering a more convenient and discreet alternative for erectile dysfunction treatment.
Viagra ODF: New Orally Dissolving Film Version Developed
Viatris developed Viagra ODF, an orally dissolving film version of Viagra, launched in Canada in September 2023 and with a UK trademark application filed, offering a more convenient and discreet alternative for erectile dysfunction treatment.
Progress
8% Bias Score
Showing 1 to 10 of 10 results